OncoQuest’s Product Pipeline

Product Pipeline

OncoQuest is focused on identifying the most effective combinations of our antigen-specific antibodies with other cytotoxic and immunomodulatory agents to enhance the clinical benefit of tumor-specific immunity in ovarian cancer, pancreatic cancer and metastatic breast cancer.

The OncoQuest technology platform includes a number of monoclonal antibodies, each specifically targeting tumorigenic proteins such as CA-125, MUC-1, PSA, and Her2/neu, and has potential for development in multiple indications.

OncoQuest believes that developing combination protocols utilizing our immuno-stimulatory antibodies, chemotherapeutic agents, checkpoint inhibitors, PARP inhibitors, and immune adjuvants, will lead to important clinical advances for patients suffering from ovarian and pancreatic cancer, and breast cancer.

Clinical trials using OncoQuest's lead product, oregovomab, in more than 950 ovarian cancer patients, indicate chemo-enhanced immunotherapy results in a more vigorous immune response associated with improved survival compared to mono-immunotherapy or chemotherapy alone.

Ovarian Cancer

Oregovomab + Chemo

Ovarian Cancer

Preclinical Phase 1 Phase 2 Phase 3 Market
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Oregovomab + nivolumab

Ovarian Cancer

Preclinical Phase 1 Phase 2 Phase 3 Market
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Oregovomab + Hiltonol®

Ovarian Cancer

Preclinical Phase 1 Phase 2 Phase 3 Market
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Oregovomab + niraparib

Ovarian Cancer

Preclinical Phase 1 Phase 2 Phase 3 Market
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

Pancreatic Cancer

Oregovomab + nelfinavir + radiation

Pancreatic Cancer

Preclinical Phase 1 Phase 2 Phase 3 Market
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Anti-MUC1 antibody + chemo

Pancreatic Cancer

Preclinical Phase 1 Phase 2 Phase 3 Market
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

Metastatic Breast Cancer

Anti-Her2/neu IgE antibody

Metastatic Breast Cancer

Preclinical Phase 1 Phase 2 Phase 3 Market
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started